These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21783382)

  • 1. The first subsequent entry biologic authorized for market in Canada: the story of Omnitrope, a recombinant human growth hormone.
    Klein AV
    Biologicals; 2011 Sep; 39(5):278-81. PubMed ID: 21783382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical programs in the development of similar biotherapeutic products: rationale and general principles.
    Berghout A
    Biologicals; 2011 Sep; 39(5):293-6. PubMed ID: 21911300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars clinical development program: confirmatory clinical trials: a virtual/simulated case study comparing equivalence and non-inferiority approaches.
    Fletcher MP
    Biologicals; 2011 Sep; 39(5):270-7. PubMed ID: 21875812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparing for subsequent entry biologics in dermatology and rheumatology in Canada.
    Papp K; Bourcier M; Ho V; Burke K; Haraoui B
    J Cutan Med Surg; 2013; 17(5):340-6. PubMed ID: 24067855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
    Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A
    Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of reviewing the follow-on biologics including Somatropin and erythropoietin in Japan.
    Arato T; Yamaguchi T
    Biologicals; 2011 Sep; 39(5):289-92. PubMed ID: 21917473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.
    Kay J; Feagan BG; Guirguis MS; Keystone EC; Klein AV; Lubiniecki AS; Mould DR; Nyarko KA; Ridgway AA; Trudeau ME; Wang J
    Biologicals; 2012 Nov; 40(6):517-27. PubMed ID: 23084808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current development in regulation of similar biotherapeutic products in Brazil.
    Castanheira LG; Barbano DB; Rech N
    Biologicals; 2011 Sep; 39(5):308-11. PubMed ID: 21868247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products.
    Njue C
    Biologicals; 2011 Sep; 39(5):266-9. PubMed ID: 21807534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenges of immunogenicity in developing biosimilar products.
    Wadhwa M; Thorpe R
    IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The story of human growth hormone--from a clone to the clinics].
    Sievi E
    Duodecim; 1997; 113(15):1460-4. PubMed ID: 10643119
    [No Abstract]   [Full Text] [Related]  

  • 16. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical trials with drugs: the influence of the authorization process].
    Carcas AJ; Serrano MA; Avendaño C; Galende I; Tristán C; García-Alonso F
    Med Clin (Barc); 1995 May; 104(18):683-8. PubMed ID: 7769877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of similar biotherapeutic products (SBPs): scientific principles and their implementation.
    Knezevic I
    Biologicals; 2011 Sep; 39(5):256-61. PubMed ID: 21907589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the impact of ICH E9.
    Brown D; Day S; Hemmings R; Wright D
    Pharm Stat; 2008; 7(2):77-87. PubMed ID: 18438957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No relaxation on drug safety and efficacy.
    Russell AS; Grace M
    World Health Forum; 1993; 14(1):31-3. PubMed ID: 8439367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.